Saad Usmani, MD, FACP, University of North Carolina School of Medicine, Chapel Hill, NC, presents the results from the primary analysis of CANDOR (NCT03158688), a multicenter, phase 3, randomized study comparing carfilzomib, dexamethasone and daratumumab (KdD) vs carfilzomib and dexamethasone (Kd) in relapsed or refractory multiple myeloma (RRMM). Patients treated with KdD showed a reduced risk of progression or death and achieved deeper responses when compared to Kd-treated patients. Overall, KdD was associated with a favorable benefit-risk profile and represents an efficacious new regimen for RRMM. This press briefing was recorded at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
